Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of

Hitomi Aono1, Mohammed Emamussalehin Choudhury1, Hiromi Higaki1

  • 1Department of Molecular and Cellular Physiology, Graduate School of Medicine, Ehime University, Toon, Ehime, Japan.

Glia
|August 25, 2017
PubMed

Insights

Activated microglia in Parkinson's disease (PD) models engulf synapses, potentially compensating for neuron loss. Suppressing this microglial activity worsens motor deficits, revealing a novel therapeutic target.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pathology

Background:

  • Parkinson's disease (PD) symptoms manifest late, after significant dopaminergic neuron loss in the substantia nigra pars compacta (SNc).
  • Compensatory mechanisms are crucial for maintaining function despite neurodegeneration.

Purpose of the Study:

  • Investigate the role of activated microglia in the substantia nigra pars reticulata (SNr) and globus pallidus (GP) in a rat model of Parkinson's disease.
  • Determine if microglia phagocytose synaptic elements and if this impacts motor function.

Main Methods:

  • Utilized a 6-hydroxydopamine-induced hemiparkinsonism rat model.
  • Examined microglial activation markers (CD68, NG2) and synaptic markers (synapsin I, PSD-95) via immunohistochemistry.
  • Tracked synaptic element engulfment using fluorescent tracers (DiI) and electron microscopy.
  • Assessed the effects of glutamate and dexamethasone on primary microglia and in vivo.

Main Results:

  • Activated microglia accumulated in the SNr, exhibiting phagocytic markers and engulfing pre- and post-synaptic elements, including NMDA receptors.
  • Microglia phagocytosed STN-derived synaptic elements, and their phagocytic activity increased with glutamate exposure.
  • Dexamethasone suppressed microglial activation in PD model rats, leading to worsened motor function and increased glutamatergic synaptic element expression.

Conclusions:

  • Microglia in the SNr and GP are activated in PD models and selectively eliminate glutamatergic synapses from the subthalamic nucleus (STN).
  • This microglial phagocytosis represents a compensatory mechanism, potentially within the basal ganglia's indirect pathway.
  • Targeting microglial activity, rather than suppressing it, may offer a novel therapeutic strategy for Parkinson's disease.